| Project/Area Number |
20591203
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
MATSUZAKI Shigenobu Kochi University, 教育研究部・医療学系, 准教授 (00190439)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKEUCHI Hiroaki 高知大学, 教育研究部・医療学系 (90346560)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | ピロリ菌 / ファージ / 除菌法 |
|---|
| Research Abstract |
Helicobacter pylori is a causative agent of gastritis and the stomach ulcer, and is also a risk factor of the stomach cancer. If H.pylori is detected at the patient's stomach, the elimination of it with the antibiotic agents is recommended. However, recent progress of antibiotic-resistance in H.pylori threatens the future of the elimination method. Therefore, we tried to get phage to develop the bacteriophage (phage) therapy system against H.pylori infection. As a result, a novel phage, φHP33, was isolated successfully. Phage φHP33 had a broad-host-range to many H.pylori strains and had strong lytic acitivity against them. Therefore, φHP33 is expected to be a good candidate as therapeutic phage for H.pylori infection.
|
